• Wegovy approved for cardiovascular indications

    Wegovy, Novo Nordisk's weight loss therapy part of a popular drug class, is now approved for reducing the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either obese or overweight, the FDA said March 8. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Sponsored
    Fill out this short survey here and attend our annual meeting for free.
  • Pharmacist group addresses second victim syndrome

    It's past time to support pharmacists during times of crisis and patient care failures, which can cause second victim syndrome, according to American Pharmacists Association CEO Michael Hogue, PharmD. 
  • FDA delays decision on Eli Lilly Alzheimer's drug

    The FDA has informed Eli Lilly that it plans to convene a panel of independent experts to learn more about the safety and efficacy of donanemab, the company's proposed Alzheimer's drug. The move delays an FDA decision on the drug until at least later this year.
  • Mark Cuban's drug startup: 2 years later

    Two years after launching a company with a few dozen discounted generics, Mark Cuban's Cost Plus Drugs now offers more than 2,000 medications, partners with hundreds of independent and grocery chain pharmacies, and manufactures its own drugs. 
  • CDC shares 1st real-world data on RSV drug

    Nirsevimab, a new monoclonal antibody treatment for respiratory syncytial virus, was 90% effective at preventing hospitalizations among infants this virus season, according to a March 7 CDC report.
  • Drugmaker to cap inhaler costs

    Boehringer Ingelheim will cap out-of-pocket costs for its inhaler products at $35 per month starting in June. 
  • After 20 years of failure, HIV vaccine research takes a turn

    Trials for experimental HIV vaccines have been fruitless for the last two decades, but recent scientific advances are spurring optimism among researchers, NBC News reported March 6. 
  • Mark Cuban's drug company partners with 1st health system

    On March 7, Franklin, Tenn.-based Community Health Systems became the first hospital system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co.
  • FDA panel backs simplified flu shot for next season

    An FDA advisory panel has unanimously recommended the agency approve a trivalent, rather than quadrivalent, flu vaccine for use next season.
  • 10 drugs poised to be best-sellers in 2024

    Merck's cancer drug Keytruda is expected to be the top-selling drug globally in 2024, according to data published by Statista.
  • FDA clears 1st OTC glucose monitor

    The FDA on March 5 cleared the Dexcom Stelo Glucose Biosensor System for use, making it the first continuous glucose monitoring device to be available over the counter.
  • RSV vaccine roll-out recap: 5 notes on safety, efficacy

    It has been 44 years since work toward a viable vaccine for respiratory syncytial virus began. But, after the inaugural roll-out of an RSV vaccine for older adults and a maternal vaccine to protect infants during the 2023-2024 viral season, new research and data have emerged.
  • HIV becoming resistant to widely used medication, WHO finds

    A common medication used to manage and treat HIV is becoming increasingly resistant, according to a report from the World Health Organization.
  • Experts optimistic in weight loss drugs as addiction treatment

    Anecdotally, patients on a popular class of weight loss drugs known as glucagon-like peptide receptor agonists are reporting another potential benefit experts are optimistic about: reduced cravings for alcohol. 
  • Mark Cuban's pharma company to start manufacturing 2 drugs this week

    Mark Cuban Cost Plus Drug Co. plans to begin manufacturing epinephrine and norepinephrine this week at its 22,000-square-foot drug facility in Dallas, Mr. Cuban confirmed to Becker's on March 5. 
  • Drugmakers send CMS counteroffers in fair price negotiations

    Drugmakers that were selected in early February to begin price negotiations for 10 of the most expensive drugs in the U.S. as part of the Biden administration's Inflation Reduction Act have sent the federal government counteroffers, President Joe Biden confirmed in a March 4 update.
  • Post-Change hack, hospital pharmacies ask for paused audits

    As hospital pharmacies try to recover from a nationwide disruption in their claims and e-prescribing technology, the American Society of Health-System Pharmacists is urging HHS to take action. 
  • Ozempic cuts risk of kidney problems in diabetes patients: New data

    Novo Nordisk released results from a clinical trial March 5 that showed Ozempic reduced the risk of kidney disease-related events in patients with Type 2 diabetes. 
  • The efficacy of GLP-1s, compared

    Prescriptions for Ozempic, Wegovy and other glucagon-like peptide-1 receptor agonists are booming among patients seeking to shed pounds. 
  • Where medication abortion is, is not legal

    Fourteen states prohibit medication abortion — a federally approved two-drug regimen that accounts for more than 50% of U.S. abortions — and 15 other states restrict abortion pills, according to NBC News. 

Featured Whitepapers

Featured Webinars